Thai H. Ho
YOU?
Author Swipe
View article: Collagen Prolyl Hydroxylases Regulate HIF-α Levels Independently of pVHL in ccRCC
Collagen Prolyl Hydroxylases Regulate HIF-α Levels Independently of pVHL in ccRCC Open
The hypoxia-inducible factors, HIF-1α and HIF-2α, are master regulators of the hypoxia response. Under ambient conditions, both are hydroxylated by the HIF prolyl hydroxylases (HIF PHDs) resulting in ubiquitination by the pVHL E3 ligase co…
View article: Phenotyping and clinical utility of phagocytic polyploid giant cancer macrophages in blood
Phenotyping and clinical utility of phagocytic polyploid giant cancer macrophages in blood Open
Historically, polyploid giant cancer cells (PGCCs) within tumors have been ignored as superfluous inflammatory refuse with no intrinsic clinical or biological relevance. However recently, multiple studies have described the existence PGCCs…
View article: SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation
SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation Open
These findings unify genome-wide screening approaches with the latest genetic and pharmacologic modeling methodologies to reveal an entirely novel epigenetic approach to individualize therapies against a challenging loss-of-function SETD2 …
View article: Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC)
Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC) Open
RNA N6-methyladenosine (m6A) plays diverse roles in RNA metabolism and its deregulation contributes to tumor initiation and progression. Clear cell renal cell carcinoma (ccRCC) is characterized by near ubiquitous loss of VHL followed by mu…
View article: Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings
Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings Open
Despite advancements in the early-stage detection and expansion of treatments for prostate cancer (PCa), patient mortality rates remain high in patients with aggressive disease and the overtreatment of indolent disease remains a major issu…
View article: <scp>SETD2</scp> loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a <scp>TGF</scp>‐β‐independent manner
<span>SETD2</span> loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a <span>TGF</span>‐β‐independent manner Open
Histone‐lysine N ‐methyltransferase SETD2 (SETD2), the sole histone methyltransferase that catalyzes trimethylation of lysine 36 on histone H3 (H3K36me3), is often mutated in clear cell renal cell carcinoma (ccRCC). SETD2 mutation and/or l…
View article: PD-L1 Expression on Circulating Antigen Presenting Macrophages in Blood Predicts PFS & OS in an Array of Metastatic Cancer Types Treated with PD-L1/PD-1 Immunotherapies
PD-L1 Expression on Circulating Antigen Presenting Macrophages in Blood Predicts PFS & OS in an Array of Metastatic Cancer Types Treated with PD-L1/PD-1 Immunotherapies Open
Cancer Associated Macrophage Like cells (CAMLs) are antigen presenting circulating stromal cells found in the blood of cancer patients (pts). Recently, PD-L1 expression on CAMLs was described in breast (BC), lung (LC) and renal cell carcin…
View article: Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>
Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i> Open
Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor …
View article: Data from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Data from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation Open
Monoclonal antibodies that target the programmed death-1 (PD-1)–programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarcomatoid differentiation in renal cell carcinoma (RCC) is associate…
View article: Supplementary Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>
Supplementary Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i> Open
*Supplementary Figure 1 shows the chemical structure of SBI-183. *Supplementary Figure 2 displays the verification of shRNA KD of QSOX1 by qRT-PCR. *Supplementary Table 1 shows the results from our docking protocols. *Supplementary Figure …
View article: Supplementary Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>
Supplementary Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i> Open
*Supplementary Figure 1 shows the chemical structure of SBI-183. *Supplementary Figure 2 displays the verification of shRNA KD of QSOX1 by qRT-PCR. *Supplementary Table 1 shows the results from our docking protocols. *Supplementary Figure …
View article: Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>
Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i> Open
Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor …
View article: Data from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Data from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation Open
Monoclonal antibodies that target the programmed death-1 (PD-1)–programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarcomatoid differentiation in renal cell carcinoma (RCC) is associate…
View article: Supplemental Table from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Supplemental Table from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation Open
Supplemental Table. Concordance of Immunohistochemical Staining of PD-L1 Expression (130021 vs SP142 antibody) in 19 Renal Cell Carcinomas With Sarcomatoid Differentiation
View article: Supplemental Table from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Supplemental Table from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation Open
Supplemental Table. Concordance of Immunohistochemical Staining of PD-L1 Expression (130021 vs SP142 antibody) in 19 Renal Cell Carcinomas With Sarcomatoid Differentiation
View article: Supplementary Table 10-12 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Supplementary Table 10-12 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas Open
Supplementary Table 10: List of samples misclassified among the clear-cell renal cell carcinomas dataset with the corresponding new classification. Among those, many of them have been demonstrated to belong to the C4 cluster of long non-co…
View article: Data from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Data from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma Open
Purpose: We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC).Experimental Design: We studied a cohort of mRCC patients who were treated with mTO…
View article: Supplementary Table S1, Figures S1-2 from Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Supplementary Table S1, Figures S1-2 from Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial Open
Supplementary Table S1, Figures S1-2. Supplementary Table S1. Comparison of treatment outcomes between the overall study population of the COMPARZ trial and the PD-L1 study population. Supplementary Figure S1. CD8+ T cells scoring system. …
View article: Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma Open
Mutational status of non-mTOR pathway genes according to responder status
View article: Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer Open
Purpose:Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel–Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-ba…
View article: Data from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Data from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas Open
Purpose: DNA methylation is a heritable covalent modification that is developmentally regulated and is critical in tissue-type definition. Although genotype–phenotype correlations have been described for different subtypes of renal cell ca…
View article: Figure S1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Figure S1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas Open
A) Box-plot for average gene expression of promoters located in CpG islands according to their methylation levels. B) Box-plot for average gene expression of promoters located outside CpG islands according to their methylation levels. Note…
View article: Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma Open
List of all patients with response status, survival status, age, sex, histology, drug treatment, and summary of mutation findings
View article: Supplementary Table 1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Supplementary Table 1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas Open
List of DNA methylation levels for each CpG sites detected by DREAM in the 2 normal kidneys and the 22 renal cell carcinomas samples. Each column represents one sample and each raw one CpG site with the relative annotations (coordinates, C…